Open Site Navigation
  • Neurana News

Neurana Pharmaceuticals to Present at Piper Sandler 32nd Annual Healthcare Conference

SAN DIEGO, Calif., November 24, 2020 -- Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson, President and Chief Executive Officer, will present at the 32nd Annual Piper Sandler Virtual Healthcare Conference and participate in one-on-one meetings with investors. The conference takes place virtually November 30th to December 3rd. Presentations will be available for registered attendees via the Piper Sandler conference site.

About Neurana Pharmaceuticals, Inc.

Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful muscle spasms of the back. The company was founded in 2013 and is based in San Diego. Neurana’s lead development compound is tolperisone, a novel, non-opioid, non-drowsy, non-cognitive impairing treatment, which the company is developing for the large population of patients who experience muscle spasms. In May 2018, Neurana completed a $60 million Series A financing led by Sofinnova Ventures with participation from Longitude Capital, New Leaf Venture Partners and H.I.G. BioHealth Partners to fund the clinical development of tolperisone. For additional information, please visit


Recent Posts

See All